Molecular glues are beginning to stick
Degron Therapeutics is featured in the article about molecular-glue drug discovery.
Degron raises $22M to develop molecular glue-based protein degradation platform
Degron Therapeutics Inc. has raised $22 million in a series A round to develop its drug development
Molecular glue firms get investment, strike partnerships
Degron is the latest to attract funding for new method of degrading proteins